AVI BioPharma Announces Third Quarter 2009 Financial Results Conference Call

BOTHELL, WA, Nov 02 (MARKET WIRE) --
AVI BioPharma, Inc. (NASDAQ: AVII), a developer of RNA-based drugs, will
hold a conference call to report third quarter 2009 financial results on
Monday, Nov. 9, 2009, at 9:30 a.m. Eastern time (6:30 a.m. Pacific time).

Individuals interested in listening to the live conference call may do so
by dialing 877-591-4956 toll free within the United States and Canada, or
719-325-4775 for international callers.

A replay of the call will be available by dialing 888-203-1112 toll free
within the U.S. and Canada or 719-457-0820 for international callers. The
passcode for the replay is 4369547. In addition, a recording of the call
will be available within approximately 24 hours at www.avibio.com.

About AVI BioPharma

AVI BioPharma is focused on the discovery and development of RNA-based
drugs utilizing proprietary derivatives of its antisense chemistry
(morpholino-modified phosphorodiamidate oligomers or PMOs) that can be
applied to a wide range of diseases and genetic disorders through several
distinct mechanisms of action. Unlike other RNA therapeutic approaches,
AVI's antisense technology has been used to directly target both messenger
RNA (mRNA) and its precursor (pre-mRNA), allowing for both up- and
down-regulation of targeted genes and proteins. AVI's RNA-based drug
programs are being evaluated for the treatment of Duchenne muscular
dystrophy as well as for the treatment of cardiovascular restenosis
through our partner Global Therapeutics, a Cook Group Company. AVI's
antiviral programs have demonstrated promising outcomes in Ebola Zaire
and Marburg Musoke virus infections and may prove applicable to other
viral targets such as influenza, HCV or Dengue viruses. For more
information, visit www.avibio.com.

"Safe Harbor" Statement under the Private Securities Litigation Reform Act
of 1995: The statements that are not historical facts contained in this
release are forward-looking statements that involve risks and
uncertainties, including, but not limited to, the results of research and
development efforts, the results of preclinical and clinical testing, the
effect of regulation by the FDA and other agencies, the impact of
competitive products, product development, commercialization and
technological difficulties, and other risks detailed in the company's
Securities and Exchange Commission filings.

AVI Press and Investor Contact:
Julie Rathbun
Investor Relations
(541) 224-2575
Investorrelations@avibio.com

Copyright 2009, Market Wire, All rights reserved.

-0-